Advertisement

Advertisement

prostate cancer

Pirkko-Liisa Irmeli Kellokumpu-Lehtinen, MD, PhD, on Prostate Cancer: Results of the SPCG-13 Trial

Pirkko-Liisa Irmeli Kellokumpu-Lehtinen, MD, PhD, of Tampere University Hospital, discusses phase III findings on adjuvant docetaxel and surveillance after radical radiotherapy for intermediate- and high-risk prostate cancer (Abstract 5000).

prostate cancer

Sumanta K. Pal, MD, and A. Oliver Sartor, MD, on Prostate Cancer: Perspectives on Outcomes for Black and White Patients

Sumanta K. Pal, MD, of City of Hope, and A. Oliver Sartor, MD, of Tulane University School of Medicine, discuss the implications of findings on black and white patients with metastatic castrate-resistant prostate cancer treated with abiraterone acetate and prednisone (Abstract LBA5009).

prostate cancer

Sumanta K. Pal, MD, and Neeraj Agarwal, MD, on Prostate Cancer: The Talapro-2 Trial

Sumanta K. Pal, MD, of the City of Hope, and Neeraj Agarwal, MD, of the Huntsman Cancer Institute, University of Utah, discuss the ongoing phase III Talapro-2 study of talazoparib with background enzalutamide in metastatic castration-resistant prostate cancer with DNA damage–repair deficiencies (Abstract TPS5091).

prostate cancer

Susan Halabi, PhD, on Prostate Cancer: Overall Survival for Black vs White Men

Susan Halabi, PhD, of Duke University Medical Center, discusses an analysis that showed an increase in overall survival in African American men vs Caucasian men, all of whom had metastatic castration-resistant prostate cancer treated with docetaxel/prednisone or a regimen containing those agents (Abstract LBA5005).

prostate cancer

Daniel J. George, MD, on Prostate Cancer: Outcomes for Black and White Patients

Daniel J. George, MD, of Duke University, discusses findings from a multicenter study of black and white patients with metastatic castrate-resistant prostate cancer treated with abiraterone acetate and prednisone (Abstract LBA5009).

prostate cancer
issues in oncology

2018 ASCO: Black Men With Advanced Prostate Cancer Treated With Chemotherapy May Have Equal or Better Survival Than White Men

An analysis of pooled data from 9 randomized phase III trials of more than 8,000 men with advanced prostate cancer who received chemotherapy shows chances of survival are as good for black men as white men. The median survival was the same in black men and white men overall (21 months), but black...

prostate cancer

2018 ASCO: Abiraterone May Be More Effective in Black Men With Advanced Prostate Cancer Than in White Men

In a prospective clinical trial of 100 men with metastatic castration-resistant prostate cancer, the response to the hormone treatment abiraterone (Yonsa, Zytiga) was greater and longer-lasting in black men than in white men. Black men were more likely to have a decline in prostate-specific antigen ...

prostate cancer

AUA 2018: Is Prostate Cancer Screening and Risk Stratification Moving Beyond the PSA Test?

New diagnostic tests for prostate cancer, as well as new information about the impact of the U.S. Preventive Services Task Force recommendations on prostate cancer screening, were presented at the 113th Annual Meeting of the American Urological Association (AUA). PSA Screening of African American...

prostate cancer

AUA 2018: Apalutamide Significantly Reduced Risk of PSA Progression in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

A post-hoc analysis from the phase III SPARTAN study that showed treatment with apalutamide (Erleada) significantly reduced the risk of prostate-specific antigen (PSA) progression in patients with nonmetastatic castration-resistant prostate cancer (CRPC) who had a rapidly rising PSA while receiving ...

prostate cancer

AUA 2018: Use of MRI for Prostate Cancer Screening and Management

Use of magnetic resonance imaging (MRI) in the diagnosis of prostate cancer is increasing and brings added value to screening and surveillance, according to new studies presented this year during the 113th Annual Meeting of the American Urological Association (AUA). Four studies highlighting the...

prostate cancer

AUA 2018: Panel Discusses New Research on Prostate Cancer Management Protocols and Treatments

Researchers presented new findings on a Korean Food and Drug Administration (KFDA)-approved robotic system, safety of testosterone therapy after prostate cancer, and active surveillance protocol for low-risk prostate cancer patients at the 113th Annual Meeting of the American Urological Association ...

prostate cancer

AUA 2018: More Than 40% of Prostate Biopsies May Have Been Avoided With Use of Assay for Detection

A multicenter study that validated the clinical performance of IsoPSA—a new blood test that has proven to be more accurate in predicting overall risk of prostate cancer than standard prostate-specific antigen (PSA)—was presented at the 13th Annual Meeting of the American Urological...

Prostate Cancer

Role of MRI in Detection of Clinically Significant Prostate Cancer: ‘Practice-Affirming’ Results From The PRECISION Trial

Simultaneously presented at the 2018 European Association of Urology meeting and published in The New England Journal of Medicine, the PRECISION trial will go down as a landmark study for solidifying the role of magnetic resonance imaging (MRI) in prostate cancer diagnosis.1 This trial provides...

Prostate Cancer

MRI-Targeted vs Standard Biopsy in Prostate Cancer Diagnosis: The PRECISION Trial

In the international PRECISION trial reported in The New England Journal of Medicine, Veeru Kasivisvanathan, MRCS, of University College London, and colleagues found that magnetic resonance imaging (MRI)-targeted biopsy resulted in a significantly higher rate of diagnosis of clinically significant ...

Solid Tumors
Prostate Cancer

Ultrahypofractionated Radiotherapy for Prostate Cancer Appears Safe and Effective

Radiotherapy given in high doses over a shorter period of time is safe and effective for patients with prostate cancer, according to research from a phase III trial presented at the European Society for Radiotherapy & Oncology (ESTRO) 37 Conference.1 The treatment—called ultrahypofractionated...

Colorectal Cancer
Breast Cancer
Hepatobiliary Cancer
Lung Cancer
Kidney Cancer
Prostate Cancer
CNS Cancers
Leukemia

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2018 Guidelines Updates

In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) covering 8 tumor types. Guidelines are now published for more than 60 tumor types and topics. Some of the key updates were presented at NCCN’s 23rd...

prostate cancer

Oxybutynin for Androgen Deprivation–Associated Hot Flashes in Prostate Cancer

In a letter to the editor of The New England Journal of Medicine, Smith et al describe successful use of oxybutynin to treat hot flashes in a patient receiving androgen-deprivation therapy (ADT) for prostate cancer. As noted by the authors, nonhormonal treatments for menopausal hot flashes in women ...

prostate cancer

USPSTF Recommendations on PSA-Based Screening for Prostate Cancer

As reported in JAMA, the US Preventive Services Task Force (USPSTF) has issued updated recommendations on prostate-specific antigen (PSA)-based screening for prostate cancer. To inform the recommendations, the USPSTF reviewed evidence on benefits and harms of PSA-based screening and treatment of...

Solid Tumors
Prostate Cancer

Should We Treat Rising PSA in Men With Castrate Androgen Levels?

In rapid succession, the SPARTAN study results were presented at the 2018 Genitourinary Cancers Symposium, the data were published in The New England Journal of Medicine,1 and the drug apalutamide -(Erleada) was approved by the U.S. Food and Drug Administration (FDA) for men with previously...

lung cancer
prostate cancer

By 2030, Prostate and Lung Cancers Are Expected to Be the Most Common Cancer Types Among HIV-Infected Adults

While effective antiretroviral therapy, which suppresses HIV replication and improves immune function, has resulted in increased longevity for people living with HIV and reduced the risk of certain cancers, including Kaposi sarcoma and non-Hodgkin lymphoma, other cancers are expected to become more ...

prostate cancer

Concordance of Non–Low-Risk Prostate Cancer Among Brother Pairs

In a Swedish study reported in the Journal of Clinical Oncology, Jansson et al identified an increased risk of non–low-risk prostate cancer among men with prostate cancer who had with brothers diagnosed with non–low-risk disease. Study Details The study involved 4,262 pairs of...

prostate cancer

ESTRO 37: Ultrahypofractionated Radiotherapy for Prostate Cancer Is Safe and Effective

Radiotherapy given in high doses over a shorter period of time is safe and effective for patients with prostate cancer, according to research from a phase III trial presented at the European Society for Radiotherapy & Oncology (ESTRO) 37 Conference (Abstract OC-0599). The...

prostate cancer

Long-Term Outcomes of Adjuvant Treatment in High-Risk Prostate Cancer

As reported by Hussain et al in the Journal of Clinical Oncology, long-term follow-up of the phase III SWOG S9921 trial showed that the addition of adjuvant mitoxantrone and prednisone (MP) to androgen-deprivation therapy (ADT) did not improve survival and increased death from other malignancies in ...

prostate cancer

Low-Dose Abiraterone With Food vs Standard-Dose Abiraterone in Castration-Resistant Prostate Cancer

In a phase II trial reported in the Journal of Clinical Oncology, Szmulewitz et al found that low-dose abiraterone (Zytiga) given with a low-fat meal was noninferior to standard-dose abiraterone in the fasting state with regard to reduction in prostate-specific antigen (PSA) levels among patients...

prostate cancer

ASCO Clinical Practice Guideline: Optimizing Anticancer Therapy in Metastatic Noncastrate Prostate Cancer

As reported in the Journal of Clinical Oncology by Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, and colleagues, ASCO has released a clinical practice guideline on optimizing anticancer therapy in men with metastatic noncastrate prostate cancer. To...

Bladder Cancer
Kidney Cancer
Prostate Cancer

GU Symposium Focuses on Prognostic Model in Urothelial Cancer, Novel Therapies for Prostate and Kidney Cancers

THE 2018 GENITOURINARY Cancers Symposium hosted an international audience of oncologists and other stakeholders to hear about the latest advances in the field. We have included coverage of many of the top news stories from the meeting in previous issues of The ASCO Post. Here are summaries of a few ...

prostate cancer

MRI-Targeted vs Standard Biopsy in Prostate Cancer Diagnosis

In the international PRECISION trial reported in The New England Journal of Medicine, Kasivisvanathan et al found that magnetic resonance imaging (MRI)-targeted biopsy resulted in a significantly higher rate of diagnosis of clinically significant prostate cancer and a lower rate of diagnosis of...

prostate cancer

Long-Term Outcomes With Standard vs Dose-Escalated Radiation Therapy in Intermediate-Risk Prostate Cancer

As reported in JAMA Oncology by Michalski et al, long-term follow-up in the NRG Oncology/RTOG 0126 trial showed no significant difference in overall survival with dose-escalated vs standard-dose radiotherapy in patients with intermediate-risk prostate cancer. High-dose radiotherapy was associated...

prostate cancer

Quality of Life With Chemohormonal Treatment in Prostate Cancer

In the E3805 trial reported in the Journal of Clinical Oncology, Morgans et al found that chemohormonal therapy with docetaxel and androgen-deprivation therapy (ADT) was associated with poorer quality of life (QOL) at 3 months but better QOL at 12 months vs ADT alone in metastatic hormone-sensitive ...

prostate cancer

Analyses of Radiographic Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer

As reported in JAMA Oncology by Rathkopf et al, sensitivity analyses of radiographic progression-free survival in the PREVAIL trial comparing enzalutamide vs placebo in metastatic castration-resistant prostate cancer support use of the measure as a clinically meaningful endpoint in trials in this...

prostate cancer

James L. Mohler, MD, on Prostate Cancer: Management Approaches

James L. Mohler, MD, of Roswell Park Cancer Institute, discusses personalized medicine, molecular risk stratification, and better androgen-deprivation therapy for men with prostate cancer.

prostate cancer

Long-Term Outcome With Finasteride Using Medicare Claims Linked to the Prostate Cancer Prevention Trial

In a study reported in the Journal of the National Cancer Institute, Unger et al linked data from the Prostate Cancer Prevention Trial (PCPT) with Medicare claims and found that finasteride treatment was associated with a maintained reduction in prostate cancer risk after discontinuation of the...

prostate cancer

EAU 2018: Prostate MRI Reveals More Clinically Significant Cancers, Reduces Overdiagnosis Compared to Standard Biopsy

A large international study has shown that magnetic resonance imaging (MRI) can reduce the number of invasive prostate biopsies by up to 28%. The PRECISION trial showed that using MRI to target prostate biopsies leads to more harmful and fewer harmless prostate cancers being diagnosed. The results...

kidney cancer
prostate cancer
bladder cancer

EAU 2018: Survey Shows Greater Suicide Rate in Patients With Urologic Cancers

A major UK survey has shown that patients with urologic cancer—such as prostate, bladder, or kidney cancer—are five times more likely to commit suicide than people without cancer. The analysis also shows that patients with cancer generally are around three times more likely to commit...

prostate cancer

Effect of Single PSA-Based Screening on Prostate Cancer Mortality

In the UK-based CAP trial reported in JAMA, Martin et al found that a single prostate-specific antigen (PSA) screening was not associated with better 10-year prostate cancer-specific survival vs the standard practice of no screening. Screening was associated with greater detection of prostate...

prostate cancer

FDA Grants Priority Review to sNDA for Enzalutamide in Nonmetastatic Castration-Resistant Prostate Cancer

On March 19, a supplemental New Drug Application (sNDA) for enzalutamide (Xtandi) was accepted for filing and granted Priority Review designation by the U.S. Food and Drug Administration (FDA). If approved, the sNDA would expand the indication of enzalutamide to include men with nonmetastatic...

prostate cancer

Study Finds Shared Decision-Making Still Lacking in Prostate Cancer Screening

A new study found many men receiving prostate-specific antigen (PSA) testing do so without a comprehensive shared decision-making process, contrary to current guidelines. The American Cancer Society study, published by Fedewa et al in Annals of Family Medicine, found that in both 2010 and 2015,...

Solid Tumors
Prostate Cancer

Targetable Immune Biology Found in Some Patients With Early-Stage Prostate Cancer

Although immunotherapy has improved outcomes across a growing number of cancers, its success in unselected cases of prostate cancer has been limited. According to data presented at the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium, however, investigators have identified a group of patients with ...

Prostate Cancer
Immunotherapy

Small Study Evaluates Novel Combination in Metastatic Prostate Cancer

The combination of the poly ADP-ribose polymerase (PARP) inhibitor olaparib (Lynparza) and the programmed cell death ligand 1 (PD-L1) inhibitor durvalumab (Imfinzi) produced positive preliminary results in men with metastatic, castration-resistant prostate cancer previously treated with...

prostate cancer

MRI-Based Model for Prostate Biopsy Risk Stratification

In a study reported in JAMA Oncology, Mehralivand et al found that inclusion of magnetic resonance imaging (MRI) findings in a predictive model may reduce unnecessary biopsies in men with suspected prostate cancer. Study Details In the study, a predictive model adding MRI-derived prostate volume...

prostate cancer

Survival With Brachytherapy-Based Radiotherapy or Radical Prostatectomy in High-Risk Localized Prostate Cancer

In a study of National Cancer Database data reported in the Journal of Clinical Oncology, Ennis et al found no significant survival differences between patients receiving brachytherapy-based radiotherapy vs radical prostatectomy in men with high-risk localized prostate cancer. Study Details The...

prostate cancer

Novel PET Imaging Agent Targets Copper in Tumors, Allowing Early Detection of Prostate Cancer Recurrence

An Italian study featured in The Journal of Nuclear Medicine demonstrates that a novel nuclear medicine imaging agent targeting copper accumulation in tumors can detect prostate cancer recurrence early in patients with biochemical relapse (ie, rising prostate-specific antigen [PSA] level). Copper...

Prostate Cancer

EXPERT POINT OF VIEW: Philip Kantoff, MD

  PHILIP KANTOFF, MD, of Memorial Sloan Kettering Cancer Center, New York, was the formal discussant of both trials. “At first glance, these are two positive trials,” Dr. Kantoff said. Although he praised the results, he said that overall survival is the best demonstration of clinical benefit, and ...

Prostate Cancer

Apalutamide, Enzalutamide Improve Metastasis-Free Survival in Nonmetastatic Castrate-Resistant Prostate Cancer

IN TWO SEPARATE TRIALS presented at the 2018 Genitourinary Cancers Symposium, apalutamide and enzalutamide (Xtandi), respectively, reduced the risk of metastasis and prolonged metastasis-free survival in men with high-risk nonmetastatic castrate-resistant prostate cancer. In the SPARTAN trial,1,2...

Prostate Cancer

New Agents for Initial Treatment of Metastatic Prostate Cancer: A New Standard of Care?

FOR DECADES, the status of metastatic prostate cancer trials was not particularly exciting. With an absence of high-impact novel agents, the focus of cancer trial groups was on the improvement of standard care. Well-crafted, large trials of hormonal therapy demonstrated the utility of combined...

prostate cancer

Multimodal Treatment in Patients With Gleason Score 9–10 Prostate Cancer

University of California, Los Angeles (UCLA) researchers have discovered that a combination of high doses of radiotherapy and hormonal therapy provides the best chance of decreasing the mortality rate in men with aggressive prostate cancer. The findings, published by Kishan et al in JAMA, also...

prostate cancer

SPARTAN Trial: Metastasis-Free Survival in Nonmetastatic Castration-Resistant Prostate Cancer

As reported by Smith et al in The New England Journal of Medicine, the phase III SPARTAN trial has shown that the androgen receptor inhibitor apalutamide (Erleada) produces significant improvement in metastasis-free survival and time to symptomatic progression vs placebo among men with...

Prostate Cancer

FDA Approves Abiraterone Acetate Plus Prednisone for High‑Risk Metastatic Castration-Sensitive Prostate Cancer

ON FEBRUARY 7, 2018, the U.S. Food and Drug Administration (FDA) approved abiraterone acetate (Zytiga) tablets in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer.  The FDA initially approved abiraterone acetate with prednisone in 2011 for patients with...

Solid Tumors
Prostate Cancer

Combined Medical and Psychological Approach May Help Couples Reclaim Intimacy After Prostate Cancer Treatment

“To what extent do treatments for prostate cancer impact sexual functioning? To a great extent,” Christian Nelson, PhD, Chief, Psychiatry Service, Memorial Sloan Kettering Cancer Center, New York, told participants at the 11th Annual Oncofertility Consortium Conference in Chicago.1 Most men with...

prostate cancer

Long-Term Survival Outcomes With Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Analysis of long-term survival outcomes in the phase III CHAARTED trial showed a survival advantage with the addition of docetaxel to androgen-deprivation therapy (ADT) in patients with hormone-sensitive metastatic prostate cancer, although no advantage was observed among patients with low-volume...

Advertisement

Advertisement

;
Advertisement